My guest for this episode is Nirao Shah, MD, PhD, professor and researcher at Stanford University School of Medicine and one of the worlds leading experts on these topics
The return of appetite is not evidence of metabolic damage but rather the removal of pharmacological appetite suppression
I value your vision, let's connect When will we see neuro readouts from the EVOKE study
This prospectively planned, pooled individual participant data cardiovascular safety meta-analysis came to the conclusion that treatment with once-weekly tirzepatide at doses of 5 mg, 10 mg, and 15 mg, with controlled treatment exposure up to 104 weeks, was not linked to an increased risk for cardiovascular events in people with T2DM across a spectrum of T2DM duration and cardiovascular risk levels
For a more personal touch, our telehealth video visits connect you with our dedicated doctors 24/7, in all 50 states, for less than $40
Some evolutionary perspectives on Alzheimers disease pathogenesis and pathology